Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-04-05 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团九届三十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 38th meeting of the 9th board of directors, including approval of a 2021 restricted stock incentive plan draft, its implementation assessment methods, and authorization requests for the shareholders' meeting. The document includes voting results and procedural details but does not contain financial statements or detailed financial performance data. It is not a full annual report, audit report, or earnings release. It is not a call transcript or investor presentation. The document is primarily about board decisions and management matters related to stock incentive plans and meeting authorizations. Therefore, it fits best under Board/Management Information (MANG). The document length is 2596 characters, which is relatively short and consistent with a board meeting resolution announcement rather than a full report. Confidence is high due to clear content and context.
2021-04-05 Chinese
昆药集团2021年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is a detailed draft of a 2021 restricted stock incentive plan for Kunming Pharmaceutical Group Co., Ltd. It includes comprehensive information about the stock incentive plan, such as the purpose, legal basis, management structure, scope of incentive recipients, stock source, quantity, distribution, effective period, grant date, lock-up period, conditions for lifting restrictions, performance targets, adjustment methods, accounting treatment, and expected impact on financial results. The document is lengthy (15,000 characters) and contains substantive content about the company's management and compensation policies related to stock incentives. It is not a simple announcement or a brief summary but a full plan document. This type of document falls under Remuneration Information filings, which detail compensation plans for executives and directors, including stock incentive plans. Therefore, the appropriate classification is DEF 14A (Remuneration Information).
2021-04-05 Chinese
昆药集团独立董事关于公司九届三十八次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Kunming Pharmaceutical Corporation regarding the company's 2021 restricted stock incentive plan. It discusses the legality, qualifications of incentive recipients, compliance with laws and regulations, and the scientific and reasonable nature of the performance indicators set in the incentive plan. There is no financial data, earnings information, or report publication announcement. The document is a formal opinion related to board matters and corporate governance concerning a stock incentive plan, which is typically classified under Board/Management Information (MANG) as it relates to decisions and opinions at the board level about management incentives and governance.
2021-04-05 Chinese
昆药集团关于使用部分闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Corporation regarding the progress of using part of its idle funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, expected yields, risk control measures, and approvals by the board and shareholders. The document is not a full financial report but rather a regulatory announcement about capital management activities, specifically the purchase of financial products using idle funds. It does not contain comprehensive financial statements or management discussion typical of annual or interim reports. It also does not fit into categories like earnings release, board changes, or legal proceedings. Given the nature of the content—an update on financing activities related to the company's capital management—the most appropriate classification is Capital/Financing Update (CAP). The document length (6682 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement. Confidence is high due to the clear focus on capital use and investment products.
2021-03-16 Chinese
昆药集团关于举行2020年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about a 2020 annual performance online briefing session scheduled for March 29, 2021. It references the 2020 annual report already disclosed on March 16, 2021, and invites investors to participate in an interactive session to discuss the company's 2020 performance. The document does not contain the actual financial report or detailed financial data but rather announces and provides details about the upcoming investor presentation event. The document length is short (1346 characters), and it serves as a notice for the event rather than the report itself. Therefore, it fits the category of an Investor Presentation (IP) announcement or related event notice. Given the detailed description of the event and the interactive nature, the best classification is Investor Presentation (IP).
2021-03-16 Chinese
昆药集团董事会关于募集资金年度存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from the board of Kunming Pharmaceutical Group Co., Ltd. regarding the annual deposit and actual use of raised funds. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange concerning the management and use of raised funds. The content includes detailed financial figures about the amounts raised through various stock issuances, the timing of fund deposits, usage of funds in specific projects, management of funds, and investment in financial products. The document is comprehensive, covering multiple years up to December 31, 2020, and includes tables and notes on fund usage, project progress, and compliance with regulatory requirements. This type of document aligns with a Capital/Financing Update (CAP) as it focuses on fundraising activities, the management of raised capital, and the actual use of those funds, rather than being a full annual report or earnings release. It is not a simple announcement or certification but a substantive report on capital management and usage.
2021-03-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.